The 10-K mentions that the company is increasing its investment in manufacturing and sourcing capabilities in order to more closely align its production capability with its sales in major geographic areas. This suggests a strategy focused on optimizing its supply chain and production footprint.

The 10-K mentions that on February 25, 2025, the Company entered into a definitive agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. for $4.1 billion. This suggests a strategic decision to divest a non-core asset.

The 10-K mentions that the company is working towards the goal of discontinuing the use of PFAS in its products. This suggests a strategic decision to reduce potential liabilities related to PFAS.

The 10-K mentions that starting in the second quarter of 2024, Solventum established its own hedging program. This suggests that management is executing on the transition to a standalone company.

The 10-K mentions that in the fourth quarter of 2024, the Company announced its Solventum Way restructuring program. This suggests that management is taking steps to improve efficiency.

The 10-K mentions that business segment operating income margin decreased when compared to the same period last year as a result of higher costs to stand-up and operate our standalone structure after Spin-Off. This suggests that management is facing challenges in executing the transition to a standalone company.

The 10-K mentions that the company may face potential liabilities related to PFAS. This is a significant risk factor for the company.

The 10-K mentions that the company is subject to risks related to international, federal, state and local treaties, laws and regulations. This is a significant risk factor for the company.

The 10-K mentions that 3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements. This is a significant risk factor for the company.

The 10-K mentions that the company operates in highly competitive markets. This is a significant risk factor for the company.

The 10-K mentions that consolidation in the healthcare industry could have an adverse effect on Solventum's revenues and results of operations. This is a significant risk factor for the company.

The 10-K mentions that the company's growth objectives are largely dependent on the timing and market acceptance of its new products and services. This is a significant risk factor for the company.

The 10-K mentions that in the fourth quarter of 2024, the Company announced its Solventum Way restructuring program. This suggests that management is taking steps to improve operational efficiency.

The 10-K mentions that the company is increasing its investment in manufacturing and sourcing capability in order to more closely align its production capability with its sales in major geographic areas. This suggests that management is taking steps to improve operational efficiency.

The 10-K mentions that Solventum's future results are subject to vulnerability with respect to materials and availability of purchased components, compounds, raw materials, energy, production capacity and labor. This suggests that the company is facing challenges in its supply chain.

The 10-K mentions that the company's growth objectives are largely dependent on the timing and market acceptance of its new products and services. This suggests that innovation is a key driver of growth.

The 10-K mentions that Solventum also intends to build artificial intelligence (“AI”) into many of its digital offerings. This suggests that the company is investing in new technologies.

The 10-K mentions that the company may be unable to obtain, maintain, protect or effectively enforce its intellectual property rights. This is a significant risk factor for the company.

The 10-K mentions that the proceeds from the issuance of senior notes were paid to 3M. This suggests that the company is prioritizing debt repayment to 3M.

The 10-K mentions that the company is increasing its investment in manufacturing and sourcing capability. This suggests that the company is prioritizing investments in its supply chain and production footprint.

The 10-K mentions that the company does not currently intend to pay any dividends. This suggests that the company is prioritizing investments in its business over returning capital to shareholders.

The 10-K mentions that the company is working towards the goal of discontinuing the use of PFAS in its products. This suggests that the company is prioritizing environmental sustainability.

The 10-K mentions that the company is subject to environmental laws and regulations. This suggests that the company is prioritizing environmental compliance.

The 10-K mentions that the company is committed to the safety, health, and well-being of its employees. This suggests that the company is prioritizing social responsibility.

The 10-K mentions that the company operates in a strictly regulated industry. This suggests that the company is subject to regulatory risks.

The 10-K mentions that the company is subject to laws and regulations governing government contracts. This suggests that the company is subject to government contract risks.

The 10-K mentions that the company is exposed to risks associated with product liability claims. This suggests that the company is subject to product liability risks.